SCHEMBL6206525

SCHEMBL6206525

CC(C)(C)OC(=O)C1(S(=O)(=O)c2ccc(-c3ccc(CCC(F)(F)C(F)(F)F)cc3)nc2)CCOCC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 12/20 0.38
MMP8 P22894 12/20 0.38
MMP2 P08253 11/20 0.38
MMP3 P08254 10/20 0.38
MMP9 P14780 10/20 0.38
MMP1 P03956 5/20 0.38
MMP7 P09237 4/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
CYP2C19 P33261 1/20 0.38
DGAT1 O75907 1/20 0.36
ADAM17 P78536 1/20 0.36
PHGDH O43175 2/20 0.36
MMP14 P50281 3/20 0.35
MMP10 P09238 1/20 0.35
MMP12 P39900 1/20 0.35
GCK P35557 1/20 0.35
GCKR Q14397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5908559 0.95 CYP3A4 (0.40) MMP13MMP8MMP2MMP3MMP9
SCHEMBL6205696 0.93 CYP3A4 (0.39) MMP13MMP8MMP2MMP3MMP9
SCHEMBL6208878 0.89 MMP2 (0.40) MMP13MMP8MMP2MMP3MMP9
SCHEMBL5908737 0.89 CYP3A4 (0.46) MMP13MMP8MMP2MMP3MMP9
SCHEMBL5908808 0.87 CYP3A4 (0.41) MMP13MMP8MMP2MMP3MMP9
SCHEMBL6206622 0.86 MMP13 (0.45) MMP13MMP8MMP2MMP3MMP9
SCHEMBL5908493 0.85 MMP13 (0.38) MMP13MMP8MMP2MMP3MMP9
Hydrochloric Acid SCHEMBL6208482 0.85 MMP2 (0.48) MMP13MMP8MMP2MMP3MMP9
SCHEMBL6208098 0.85 CYP3A4 (0.41) MMP13MMP8MMP2MMP3MMP9
SCHEMBL5908743 0.85 MMP13 (0.41) MMP13MMP8MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 MMP13 2/4885MMP8 28/4885MMP2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.